Form 4: Labcorp CEO nets 58,470 shares; covers taxes
Insider Ownership Change (Form 4)
CEO Adam H. Schechter received 58,470 Labcorp shares from a 2023 performance award and withheld 26,106 shares for taxes, bringing direct holdings to 113,137.
Summary
- Reporting person: Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc. (LH).
- On 2026-03-26, 58,470 common shares were acquired at $0 pursuant to a performance award granted on 2023-02-07 tied to performance through 2025-12-31.
- On 2026-03-26, 26,106 shares were disposed (Code F) at $268.38 to satisfy tax withholding obligations.
- Post-transaction direct beneficial ownership stands at 113,137 common shares.
- No derivative securities transactions were reported.
- Form 4 was signed on 2026-03-30 by an attorney-in-fact for Adam H. Schechter.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral-to-slightly positive signal: a performance award vested and there were no discretionary insider sales beyond routine tax withholding.
Positives
- Performance-based equity award vested, resulting in issuance of 58,470 shares.
- No open-market sale beyond tax withholding; direct beneficial ownership increased to 113,137 shares.
- Transactions are routine for equity compensation settlement and tax compliance.
Future Outlook
No forward-looking statements or guidance; disclosure relates solely to insider share acquisition from performance award vesting and tax withholding.
Management Comments
- Shares acquired on 2026-03-26 pursuant to a performance award granted on 2023-02-07 relating to performance during the three-year period ended 2025-12-31.
- Stock withholding executed to satisfy tax withholding obligations.
Industry Context
StockSavvy.ai notes that Q1 vesting and settlement of multi-year performance stock awards, accompanied by non-discretionary tax-withholding share dispositions (Code F), is a standard practice across healthcare services and diagnostics peers and typically carries limited informational content beyond confirmation of award certification.
Comparison to Industry Standards
- Consistent with peers such as Quest Diagnostics (DGX) and HCA Healthcare (HCA), where executives commonly receive multi-year PSU vesting in Q1 following compensation committee certification, with shares withheld to cover taxes at prevailing market prices.
- Disposition coded as F (tax withholding) aligns with standard executive compensation settlement practices and is generally viewed differently from discretionary open-market sales.
- Absence of derivative exercises or discretionary sales mirrors routine settlement seen at large-cap healthcare services companies during annual equity award vesting cycles.
Stakeholder Impact
- CEO’s direct ownership increases to 113,137 shares, aligning interests with shareholders.
- No discretionary selling pressure indicated; only tax-withholding shares were disposed.
- Confirms certification and settlement of a multi-year performance award tied to 2023–2025 performance.
Key Dates
| Date | Description |
|---|---|
| 2023-02-07 | Grant date of performance award to Adam H. Schechter. |
| 2025-12-31 | End of the three-year performance period for the 2023 award. |
| 2026-03-26 | 58,470 shares acquired via vested performance award; 26,106 shares withheld/disposed to cover taxes at $268.38. |
| 2026-03-30 | Form 4 signed by Attorney-in-Fact for Adam H. Schechter. |
Keywords
Labcorp Holdings Inc., LH, Adam H. Schechter, Form 4, insider ownership, executive compensation, performance stock units, PSU vesting, tax withholding, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.